Ultragenyx Pharma (RARE) PT Lowered to $70 at Baird; Multiple Milestones Ahead
Tweet
Share
E-mailGet Alerts RARE Hot Sheet
Price: $15.30 +3.03%
Rating Summary:
13 Buy, 12 Hold, 1 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 0 | Down: 1 | New: 0
Rating Summary:
13 Buy, 12 Hold, 1 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 0 | Down: 1 | New: 0
Join SI Premium – FREE
Baird lowered its price target on Ultragenyx Pharma (NASDAQ: RARE) to $70.00 (from $80.00) while maintaining an Outperform rating.
Analyst Michael Ulz notes building momentum with multiple commercial and clinical milestones in 2018.
"Notable catalysts remain on track for UX007, including potential for early filing in FAOD (update mid-2018) and Phase 3 data in Glut 1 DS movement (2H18)," he commented.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Jefferies Downgrades Xior Student Housing NV (XIOR:BB) to Hold
- Morgan Stanley Downgrades Ultragenyx Pharma (RARE) to Equalweight
- RBC Capital Downgrades Spire Healthcare (SPI:LN) (SRRHF) to Sector Perform
Create E-mail Alert Related Categories
Analyst Comments, Analyst PT ChangeRelated Entities
Robert W BairdSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
